GlobalData has reviewed the growth of global clinical trials in the immuno-oncology (IO) space that were initiated between 2008 and 2017. IO trials were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center using an ‘immuno-oncology’ filter based on drugs tagging.
Immuno-oncology therapies are separated into four broad segments:
- Adoptive cellular therapy, which includes chimeric antigen receptor T-cell immunotherapy (CAR-T), cytotoxic T lymphocyte immunotherapy (CTL), natural killer cell immunotherapy (NKT), regulatory T cells (Treg), and tumor-infiltrating lymphocyte immunotherapy (TIL).
- Immune checkpoint modulators.
- Immune system modulators, which include various cancer vaccines.
- Immunomodulatory enzyme inhibitors.
The highest growth was attributed to immune checkpoint modulators, where the number of trials increased at a much higher rate than the other IO segments, concurrent with the surge in investigations into PD-1 targets (see Figure 1).
Figure 1: global IO clinical trials, N, by segment
Source: GlobalData. © GlobalData
GlobalData (2017). PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities, August 2017, Report Code: GDHC009PFR.
For more insight and data, visit the GlobalData Report Store – Drug Development Technology is part of GlobalData Plc.